SCHEMBL30765618

SCHEMBL30765618

CC(C)(C)OC(=O)NCc1c(F)c2cnccc2n1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.41
▸ LATS1 O95835 5/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ LATS2 Q9NRM7 1/20 0.38
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ GPR119 Q8TDV5 2/20 0.35
▸ GABRG2 P18507 1/20 0.35
▸ GABRB3 P28472 1/20 0.35
▸ GABRA5 P31644 1/20 0.35
▸ BTK Q06187 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ GRM2 Q14416 1/20 0.34
▸ ACVR1B P36896 1/20 0.34
▸ TGFBR1 P36897 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27149698 0.76 NAMPT (0.42) NAMPTLATS1CYP3A4LATS2L3MBTL1
SCHEMBL38662549 0.76 LATS1 (0.44) NAMPTLATS1CYP3A4LATS2L3MBTL1
SCHEMBL17790284 0.73 BTK (0.39) CYP3A4SCN9AGPR119GABRG2GABRB3
SCHEMBL27140815 0.73 NAMPT (0.42) NAMPTLATS1CYP3A4LATS2L3MBTL1
SCHEMBL23478372 0.72 NAMPT (0.43) NAMPTLATS1CYP3A4LATS2CA12
SCHEMBL31558589 0.72 NAMPT (0.43) NAMPTLATS1CYP3A4LATS2CA12
SCHEMBL29773883 0.71 CHRM2 (0.49) L3MBTL1GPR119GABRG2GABRB3GABRA5
SCHEMBL3889015 0.70 HTR6 (0.46) LATS1CYP3A4LATS2L3MBTL1LMNA
SCHEMBL31751595 0.68 NAMPT (0.43) NAMPTLATS1CYP3A4LATS2KDM4E
SCHEMBL16637537 0.68 GABRG2 (0.37) NAMPTLATS1GPR119GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 — — EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 — — CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 — — WO disclosed
Send feedback